Etazolate hydrochloride

Pricing Availability Delivery Time Qty
Cat.No. 0438 - Etazolate hydrochloride | C14H19N5O2.HCl | CAS No. 35838-58-5
Description: PDE4 inhibitor
Chemical Name: 1-Ethyl-4-[(1-methylethylidene)hydrazino]-1H-pyrazolo-[3,4-b]-pyridine-5-carboxylic acid, ethyl ester hydrochloride
Purity: ≥98% (HPLC)

Biological Activity

Phosphodiesterase inhibitor, selective for PDE4 (IC50 = 2.0 μM).

Technical Data

M. Wt 325.8
Formula C14H19N5O2.HCl
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 35838-58-5
PubChem ID 37274
Smiles CCN2C1=NC=C(C(OCC)=O)C(NN=C(C)C)=C1C=N2.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 32.58 100
water 50

Preparing Stock Solutions

The following data is based on the product molecular weight 325.8. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.07 mL 15.35 mL 30.69 mL
5 mM 0.61 mL 3.07 mL 6.14 mL
10 mM 0.31 mL 1.53 mL 3.07 mL
50 mM 0.06 mL 0.31 mL 0.61 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet


References are publications that support the products' biological activity.

Ahluwalia and Nicholson et al (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. TiPS 12 19 PMID: 1848733

Chesin et al (1972) 1-Ethyl-4-(isopropylidenehydrazinol-H-pyrazolo-(3,4-b)-pyridin-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009) - potent new inhibitor of cyclic 3'5-nucleotide phosphodiesterase. Biochem.Pharmacol. 21 2443 PMID: 4345859

Rhoads (1982) Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction. Biochem.Pharmacol. 31 665 PMID: 6177320

If you know of a relevant reference for Etazolate hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Phosphodiesterase Inhibitors

Keywords: Etazolate hydrochloride, supplier, PDE4, inhibitors, inhibits, PDE, Phosphodiesterases, Phosphodiesterases, Phosphodiesterases, Tocris Bioscience

Citations for Etazolate hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for Etazolate hydrochloride. Do you know of a great paper that uses Etazolate hydrochloride from Tocris? If so please let us know.

Reviews for Etazolate hydrochloride

There are currently no reviews for this product. Be the first to review Etazolate hydrochloride and earn rewards!

Have you used Etazolate hydrochloride?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area


Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.